Pioglitazone: a valuable component of combination therapy for type 2 diabetes mellitus

Bibliography

• Yang W, Lu J, Weng J, China National Diabetes and Metabolic Disorders Study Group. Prevalence of diabetes among men and women in China. N Engl J Med 2010;362:1090-101
   PubMed Web of Science ®Google Scholar
• Kahn SE, Hull RL, Utzschneider KM. Mechanisms linking obesity to insulin resistance and type 2 diabetes. Nature 2006;444:840-6
   PubMed Web of Science ®Google Scholar
• Nathan DM, Buse JB, Davidson MB, American Diabetes Association; European Association for the Study of Diabetes. Medical management of hyperglycaemia in type 2 diabetes mellitus: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetologia 2009;52:17-30
   PubMed Web of Science ®Google Scholar
• Forst T, Hanefeld M, Pfutzner A. Review of approved pioglitazone combinations for type 2 diabetes. Expert Opin Pharamacother 2011;12(10):1571-84
   PubMed Web of Science ®Google Scholar
• Charbonnel BH, Matthews DR, Schernthaner G, QUARTET Study Group. A long-term comparison of pioglitazone and gliclazide in patients with type 2 diabetes mellitus: a randomized, double-blind, parallel-group comparison trial. Diabet Med 2005;22:399-405
   PubMed Web of Science ®Google Scholar
• Perriello G, Pampanelli S, Di Pietro C, Italian Pioglitazone Study Group. Comparison of glycaemic control over 1 year with pioglitazone or gliclazide in patients with type 2 diabetes. Diabet Med 2006;23:246-52
   PubMed Web of Science ®Google Scholar
• Tan M, Johns D, Gonzalez Galvez G, GLAD Study Group. Effects of pioglitazone and glimepiride on glycemic control and insulin sensitivity in Mexican patients with type 2 diabetes mellitus: a multicenter, randomized, double-blind, parallel-group trial. Clin Ther 2004;26:680-93
   PubMed Web of Science ®Google Scholar
• Tan MH, Baksi A, Krahulec B, GLAL Study Group. Comparison of pioglitazone and gliclazide in sustaining glycemic control over 2 years in patients with type 2 diabetes. Diabetes Care 2005;28:544-50
   PubMed Web of Science ®Google Scholar
• Home PD, Pocock SJ, Beck-Nielsen H, RECORD Study Team. Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): a multicentre, randomised, open-label trial. Lancet 2009;373:2125-35
   PubMed Web of Science ®Google Scholar
• Rizos CV, Liberopoulos EN, Mikhailidis DP, Elisaf MS. Pleiotropic effects of thiazolidinediones. Expert Opin Pharmacother 2008;9:1087-108
   PubMed Web of Science ®Google Scholar
• Katsiki N, Georgiadou E, Hatzitolios AI. The role of insulin-sensitizing agents in the treatment of polycystic ovary syndrome. Drugs 2009;69:1417-31
   PubMedGoogle Scholar
• Papanas N, Maltezos E. Oral antidiabetic agents: anti-atherosclerotic properties beyond glucose lowering? Curr Pharm Des 2009;15:3179-92
   PubMed Web of Science ®Google Scholar
• Zhao Y, He X, Huang C, The impacts of thiazolidinediones on circulating C-reactive protein levels in different diseases: a meta-analysis. Diabetes Res Clin Pract 2010;90:279-87
   PubMed Web of Science ®Google Scholar
• Gonzalez-Ortiz M, Hernandez-Salazar E, Kam-Ramos AM, Martinez-Abundis E. Effect of pioglitazone on insulin secretion in patients with both impaired fasting glucose and impaired glucose tolerance. Diabetes Res Clin Pract 2007;75:115-18
   PubMed Web of Science ®Google Scholar
• Derosa G, Cicero AF, D'Angelo A, Effects of 1 year of treatment with pioglitazone or rosiglitazone added to glimepiride on lipoprotein (a) and homocysteine concentrations in patients with type 2 diabetes mellitus and metabolic syndrome: a multicenter, randomized, double-blind, controlled clinical trial. Clin Ther 2006;28:679-88
   PubMed Web of Science ®Google Scholar
• Derosa G, D'Angelo A, Ragonesi PD, Metformin-pioglitazone and metformin-rosiglitazone effects on non-conventional cardiovascular risk factors plasma level in type 2 diabetic patients with metabolic syndrome. J Clin Pharm Ther 2006;31:375-83
   PubMed Web of Science ®Google Scholar
• Karamanos B, Thanopoulou A, Drossinos V, Study comparing the effect of pioglitazone in combination with either metformin or sulphonylureas on lipid profile and glycaemic control in patients with type 2 diabetes (ECLA). Curr Med Res Opin 2011;27:303-13
   PubMed Web of Science ®Google Scholar
• Agouridis AP, Filippatos TD, Derdemezis CS, Combination of fenofibrate with non-statin drug regimens. Curr Pharm Des 2010;16:3401-16
   PubMed Web of Science ®Google Scholar
• Yamagishi S, Ogasawara S, Mizukami H, Correction of protein kinase C activity and macrophage migration in peripheral nerve by pioglitazone, peroxisome proliferator activated-gamma-ligand, in insulin-deficient diabetic rats. J Neurochem 2008;104:491-9
   PubMedGoogle Scholar
• Maeda T, Kiguchi N, Kobayashi Y, Pioglitazone attenuates tactile allodynia and thermal hyperalgesia in mice subjected to peripheral nerve injury. J Pharmacol Sci 2008;108:341-7
   PubMed Web of Science ®Google Scholar
• Sarafidis PA, Stafylas PC, Georgianos PI, Effect of thiazolidinediones on albuminuria and proteinuria in diabetes: a meta-analysis. Am J Kidney Dis 2010;55:835-47
   PubMed Web of Science ®Google Scholar
• Rizos CV, Elisaf MS, Mikhailidis DP, Liberopoulos EN. How safe is the use of thiazolidinediones in clinical practice? Expert Opin Drug Saf 2009;8:15-32
   PubMed Web of Science ®Google Scholar
• Mudaliar S, Chang AR, Henry RR. Thiazolidinediones, peripheral edema, and type 2 diabetes: incidence, pathophysiology, and clinical implications. Endocr Pract 2003;9:406-16
   PubMedGoogle Scholar
• Lecka-Czernik B. Bone loss in diabetes: use of antidiabetic thiazolidinediones and secondary osteoporosis. Curr Osteoporos Rep 2010;8:178-84
   PubMedGoogle Scholar
• Singh S, Loke YK, Furberg CD. Long-term risk of cardiovascular events with rosiglitazone: a meta-analysis. JAMA 2007;298:1189-95
   PubMed Web of Science ®Google Scholar
• Nissen SE, Wolski K. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med 2007;356:2457-71
   PubMed Web of Science ®Google Scholar
• Nissen SE, Wolski K. Rosiglitazone revisited: an updated meta-analysis of risk for myocardial infarction and cardiovascular mortality. Arch Intern Med 28 Jun 2010 [Epub ahead of print].
   Google Scholar
• Gale EA. Therapy: the second time as farce: rosiglitazone and the regulators. Nat Rev Endocrinol 2011;7:5-6
   PubMedGoogle Scholar
• Doggrell SA. Clinical trials with thiazolidinediones in subjects with type 2 diabetes – is pioglitazone any different from rosiglitazone? Expert Opin Pharmacother 2008;9:405-20
   PubMed Web of Science ®Google Scholar
• Wilcox R, Bousser MG, Betteridge DJ, PROactive Investigators. Effects of pioglitazone in patients with type 2 diabetes with or without previous stroke: results from PROactive (prospective pioglitazone clinical trial in macrovascular events 04). Stroke 2007;38:865-73
   PubMed Web of Science ®Google Scholar
• Erdmann E, Dormandy JA, Charbonnel B, ; PROactive Investigators. The effect of pioglitazone on recurrent myocardial infarction in 2,445 patients with type 2 diabetes and previous myocardial infarction: results from the PROactive (PROactive 05) Study. J Am Coll Cardiol 2007;49:1772-80
   PubMed Web of Science ®Google Scholar
• Erdmann E, Spanheimer R, Charbonnel B, PROactive Study Investigators. Pioglitazone and the risk of cardiovascular events in patients with type 2 diabetes receiving concomitant treatment with nitrates, renin-angiotensin system blockers, or insulin: results from the PROactive study (PROactive 20). J Diabetes 2010;2:212-20
   PubMedGoogle Scholar
• Schernthaner G, Chilton RJ. Cardiovascular risk and thiazolidinediones – what do meta-analyses really tell us? Diabetes Obes Metab 2010;12:1023-35
   PubMed Web of Science ®Google Scholar
• Dormandy JA, Charbonnel B, Eckland DJ, PROactive investigators. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (prospective pioglitazone clinical trial in macrovascular events): a randomised controlled trial. Lancet 2005;366:1279-89
   PubMed Web of Science ®Google Scholar
• Lincoff AM, Wolski K, Nicholls SJ, Nissen SE. Pioglitazone and risk of cardiovascular events in patients with type 2 diabetes mellitus: a meta-analysis of randomized trials. JAMA 2007;298:1180-8
   PubMed Web of Science ®Google Scholar
• Nishio K, Kobayashi Y. Different effects of thiazolidinediones on target vessel revascularization with bare metal stents: a meta-analysis. Cardiovasc Revasc Med 2010;11:227-31
   PubMedGoogle Scholar
• Hong SJ, Kim ST, Kim TJ, Cellular and molecular changes associated with inhibitory effect of pioglitazone on neointimal growth in patients with type 2 diabetes after zotarolimus-eluting stent implantation. Arterioscler Thromb Vasc Biol 2010;30:2655-65
   PubMedGoogle Scholar
• Berneis K, Rizzo M, Stettler C, Comparative effects of rosiglitazone and pioglitazone on fasting and postprandial low-density lipoprotein size and subclasses in patients with type 2 diabetes. Expert Opin Pharmacother 2008;9:343-9
   PubMed Web of Science ®Google Scholar
• Ahmed I, Furlong K, Flood J, Dual PPAR alpha/gamma agonists: promises and pitfalls in type 2 diabetes. Am J Ther 2007;14:49-62
   PubMedGoogle Scholar
• Buse JB, Rubin CJ, Frederich R, Muraglitazar, a dual (alpha/gamma) PPAR activator: a randomized, double-blind, placebo-controlled, 24-week monotherapy trial in adult patients with type 2 diabetes. Clin Ther 2005;27:1181-95
   PubMed Web of Science ®Google Scholar
• Kendall DM, Rubin CJ, Mohideen P, Improvement of glycemic control, triglycerides, and HDL cholesterol levels with muraglitazar, a dual (alpha/gamma) peroxisome proliferator-activated receptor activator, in patients with type 2 diabetes inadequately controlled with metformin monotherapy: a double-blind, randomized, pioglitazone-comparative study. Diabetes Care 2006;29:1016-23
   PubMed Web of Science ®Google Scholar
• Henry RR, Lincoff AM, Mudaliar S, Effect of the dual peroxisome proliferator-activated receptor-alpha/gamma agonist aleglitazar on risk of cardiovascular disease in patients with type 2 diabetes (SYNCHRONY): a phase II, randomised, dose-ranging study. Lancet 2009;374:126-35
   PubMed Web of Science ®Google Scholar
• Cavender MA, Lincoff AM. Therapeutic potential of aleglitazar, a new dual PPAR-alpha/gamma agonist: implications for cardiovascular disease in patients with diabetes mellitus. Am J Cardiovasc Drugs 2010;10:209-16
   PubMed Web of Science ®Google Scholar
• Kawashima S, Matsuoka TA, Kaneto H, Effect of alogliptin, pioglitazone and glargine on pancreatic beta-cells in diabetic db/db mice. Biochem Biophys Res Commun 2011;404:534-40
   PubMed Web of Science ®Google Scholar
• Wang AP, Li X, Zheng Y, Thiazolidinediones protect mouse pancreatic beta-cells directly from cytokine-induced cytotoxicity through PPARgamma-dependent mechanisms. Acta Diabetol 10 Dec 2010 [Epub ahead of print] Doi: 10.1007/s00592-010-0239-8.
   Google Scholar
• Derosa G. Efficacy and tolerability of pioglitazone in patients with type 2 diabetes mellitus: comparison with other oral antihyperglycaemic agents. Drugs 2010;70:1945-61
   PubMed Web of Science ®Google Scholar